Virpax Pharmaceuticals, Inc. (VRPX)
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.
Sector: Biotechnology
Industry: Biotechnology
Virpax Pharmaceuticals, Inc.
OTC:VRPXHealthcare · Biotechnology
$0.0003
Prev close$0.0003Close$0.0003
Mkt Cap$373
Float1.06M
O/S1.24M
VOL687 sh
$ Vol$0
RVOL0.49×
Inst Own-
Dilution
Financials Summary
Revenue$0
Net Income-$12.07M
Total Assets$1.56M
Free Cash Flow-$16.71B
Debt & Equity
Total Debt$0
Total Equity-$914K
Shares Outstanding
Short Interest
Split History2 splits · 2 reverse
2-year cumulative
1:25
Nasdaq bars a compliance period at 1:250
- 1:25Reverse splitMar 21, 202525 shares → 1
- 1:10Reverse splitMar 1, 202410 shares → 1
Balance Sheet Details
Assets$1.56M
Liabilities$2.47M
Accounts Receivable$0
Accounts Payable$0
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $5.82M | $5.12M | $10.76M | $4.84M | $1.29M | $623K | $1.14M |
| Selling, General, and Administrative | $6.26M | $7.82M | $11.08M | $7.19M | $2.9M | $2.56M | $1.48M |
| Other | $0 | $2.75M | $194K | $62K | $4K | $0 | $0 |
| Total Operating Expenses | $12.08M | $15.69M | $21.85M | $12.03M | $4.2M | $3.18M | $2.63M |
| Operating Income (EBIT) | -$12.08M | -$15.69M | -$21.85M | -$12.03M | -$4.2M | -$3.18M | -$2.63M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $104K | $0 | $0 | $93K | $148K | $125K | $15K |
| Interest Income | $0 | $0 | $0 | $0 | $148 | $125 | $0 |
| Other Income (Expense) | $13K | $500K | $194K | -$31K | -$144K | -$125K | -$15K |
| Income Before Tax (EBT) | -$12.07M | -$15.19M | -$21.65M | -$12.06M | -$4.34M | -$3.31M | -$2.64M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$12.07M | -$15.19M | -$21.46M | -$12.15M | -$4.49M | -$3.43M | -$2.64M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -70.91 | -12.97 | -18.32 | -10.37 | -9.07 | -6.58 | -0.53 |
| Diluted EPS | -70.91 | -12.97 | -18.32 | -10.37 | -9.07 | -6.58 | -0.53 |
| Weighted Average OS | 4.25M | 1.17M | 1.17M | 1.17M | 494,515 | 521,515 | 4.95M |
| EBITDA | -$11.96M | -$2.25M | -$3.31M | $62K | $4K | $0 | $0 |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $1.51M | $9.14M | $19M | $36.84M | $55K | $42K | $48K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $1.51M | $9.14M | $19M | $36.84M | $55K | $42K | $48K |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $1K | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $3K | $0 |
| Other Current Assets | $38K | $283K | $496K | $2.57M | $535 | $467 | $11K |
| Total Current Assets | $1.56M | $9.63M | $19.67M | $39.57M | $73K | $47K | $62K |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $0 | $392K | $0 | $0 |
| Total Long-Term Assets | $0 | $0 | $0 | $0 | $392K | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $1.56M | $9.63M | $19.67M | $39.57M | $465K | $47K | $62K |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $0 | $18K | $38K | $20K | $22K | $3K | $7K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $544K | $1.26M | $500K |
| Current Income Tax Payable | $0 | $0 | $0 | $8K | $13K | $14K | $7K |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | -$1.05M | -$3 | -$7K |
| Other Current Liabilities | $1.55M | $6M | $2M | $0 | $1.03M | $820K | $7K |
| Total Current Liabilities | $2.47M | $7.69M | $3.09M | $2.09M | $3.66M | $2.78M | $1.25M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $1.02M | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $0 | $0 | $1K | $0 | $1.02M | $0 | $500K |
| Other Liabilities | $0 | $0 | -$1K | $0 | $0 | $0 | -$500K |
| Total Liabilities | $2.47M | $7.69M | $3.09M | $2.09M | $4.68M | $2.78M | $1.25M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $149 | $12 | $117 | $117 | $31 | $30 | $29 |
| Retained Earnings | -$71.61M | -$59.54M | -$44.35M | -$22.7M | -$10.65M | -$6.31M | -$3M |
| Comprehensive Income & Other | $0 | -$0 | -$0 | -$0 | $0 | -$0 | $0 |
| Other Stockholders' Equity | $70.7M | $61.48M | $60.93M | $60.19M | $6.43M | $3.58M | $1.81M |
| Total Equity | -$914K | $1.93M | $16.58M | $37.48M | -$4.22M | -$2.73M | -$1.19M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $1.56M | $9.63M | $19.67M | $39.57M | $465K | $47K | $62K |
| Supplementary Data | |||||||
| Total Debt | $0 | $0 | $0 | $0 | $1.57M | $1.26M | $500K |
| Net Debt | -$1.51M | -$9.14M | -$19M | -$36.84M | $1.51M | $1.22M | $452K |
Cash Flow Statement
| Period | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | |||||||
| Net Income | -$12.07M | -$15.19M | -$21.65M | -$12.06M | -$4.34M | -$3.31M | -$2.64M |
| Depreciation & Amortization | $0 | $12.94M | $18.35M | $12.03M | $4.2M | $3.18M | $2.63M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $134.7M | $545K | $745K | $974K | $1.47M | $678K | $385K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $0 | -$993K | -$687K | $1.34M | $924K | $455K |
| Other Working Capital | -$4.78M | $4.19M | $4.05M | -$2.71M | -$13K | $8K | -$13K |
| Total Working Capital Change | -$4.78M | $4.19M | $3.06M | -$3.4M | $1.33M | $932K | $441K |
| Other Non-Cash Items | -$16.83B | -$12.34M | -$18.35M | -$12.09M | -$4.04M | -$2.62M | -$2.61M |
| Net Cash from Operating | -$16.71B | -$9.85M | -$17.85M | -$14.54M | -$1.38M | -$1.13M | -$1.8M |
| Investing Activities | |||||||
| Capital Expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | $1.5M | -$72K | -$500K | -$555K |
| Common Stock Issuance | $6.32M | $0 | $0 | $58.02M | $1.38M | $625K | $1.12M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $9.08B | $0 | $0 | -$5.19M | -$51K | $625K | $0 |
| Net Cash from Financing | $9.08B | $0 | $0 | $51.33M | $1.4M | $1.13M | $1.67M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$7.63B | -$9.85M | -$17.85M | $36.79M | $13K | -$7K | -$125K |
| Supplementary Data | |||||||
| Operating Cash Flow | -$16.71B | -$9.85M | -$17.85M | -$14.54M | -$1.38M | -$1.13M | -$1.8M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$16.71B | -$9.85M | -$17.85M | -$14.54M | -$1.38M | -$1.13M | -$1.8M |
| Cash at Beginning | $9.14B | $19M | $36.84M | $55K | $42K | $48K | $173K |
| Cash at End | $1.51B | $9.14M | $19M | $36.84M | $55K | $42K | $48K |